JP2018512585A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512585A5 JP2018512585A5 JP2017548041A JP2017548041A JP2018512585A5 JP 2018512585 A5 JP2018512585 A5 JP 2018512585A5 JP 2017548041 A JP2017548041 A JP 2017548041A JP 2017548041 A JP2017548041 A JP 2017548041A JP 2018512585 A5 JP2018512585 A5 JP 2018512585A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- ecgf
- level
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 238000000034 method Methods 0.000 claims 13
- 102000013537 Thymidine Phosphorylase Human genes 0.000 claims 11
- 108700023160 Thymidine phosphorylases Proteins 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 238000011122 anti-angiogenic therapy Methods 0.000 claims 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 239000013060 biological fluid Substances 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382109.5 | 2015-03-11 | ||
| EP15382109.5A EP3067698A1 (en) | 2015-03-11 | 2015-03-11 | Pd-ecgf as biomarker of cancer |
| PCT/EP2016/055143 WO2016142471A1 (en) | 2015-03-11 | 2016-03-10 | Pd-ecgf as biomarker of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144291A Division JP2020201278A (ja) | 2015-03-11 | 2020-08-28 | 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018512585A JP2018512585A (ja) | 2018-05-17 |
| JP2018512585A5 true JP2018512585A5 (cg-RX-API-DMAC10.html) | 2019-04-04 |
Family
ID=52737037
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548041A Pending JP2018512585A (ja) | 2015-03-11 | 2016-03-10 | 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ |
| JP2020144291A Pending JP2020201278A (ja) | 2015-03-11 | 2020-08-28 | 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ |
| JP2022113650A Active JP7453284B2 (ja) | 2015-03-11 | 2022-07-15 | 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020144291A Pending JP2020201278A (ja) | 2015-03-11 | 2020-08-28 | 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ |
| JP2022113650A Active JP7453284B2 (ja) | 2015-03-11 | 2022-07-15 | 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11802874B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3067698A1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP2018512585A (cg-RX-API-DMAC10.html) |
| KR (1) | KR102513020B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN107667292B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2016231086B8 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2896056T3 (cg-RX-API-DMAC10.html) |
| HK (1) | HK1250582A1 (cg-RX-API-DMAC10.html) |
| MX (1) | MX384046B (cg-RX-API-DMAC10.html) |
| PL (1) | PL3268744T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2016142471A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3740755B9 (en) * | 2018-01-15 | 2023-10-04 | Fundación Instituto de Investigación Sanitaria De Santiago de Compostela (FIDIS) | Use of the tas1r3 protein as a marker for therapeutic, diagnostic, and/or prognostic purposes for tumors that express said protein |
| US12624695B2 (en) | 2024-09-19 | 2026-05-12 | Mahle International Gmbh | Oil separator for compressor and compressor with oil separator |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3268147B2 (ja) * | 1994-12-28 | 2002-03-25 | 大鵬薬品工業株式会社 | モノクローナル抗体 |
| WO2003086299A2 (en) | 2002-04-09 | 2003-10-23 | Government Of The United States Of America, Represnted By The Secretary, Department Of Health And Huuman Service | Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule |
| CA2505416A1 (en) | 2002-11-21 | 2004-06-10 | Wyeth | Methods for diagnosing rcc and other solid tumors |
| JP4614952B2 (ja) | 2003-08-20 | 2011-01-19 | オンコセラピー・サイエンス株式会社 | 腎細胞癌（ｒｃｃ）の潜在的な新規治療標的としての低酸素誘導タンパク質２（ｈｉｇ２） |
| EP1510588B1 (en) | 2003-08-28 | 2007-01-31 | Roche Diagnostics GmbH | Correlation of the ratio of thymidine phosphorylase and dihydropyrimidine dehydrogenase mRNA expression levels in colorectal cancer with disease-free survival in 5-FU treated patients |
| WO2007115376A1 (en) | 2006-04-11 | 2007-10-18 | The University Of Western Australia | Anti-angiogenic agents and methods of their use |
| US8642349B1 (en) * | 2006-08-11 | 2014-02-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Artificial neural network proteomic tumor classification |
| US20130178383A1 (en) * | 2008-11-12 | 2013-07-11 | David Spetzler | Vesicle isolation methods |
| IL313131A (en) * | 2009-02-11 | 2024-07-01 | Caris Mpi Inc | Molecular characterization of tumors |
| US20120282631A1 (en) * | 2009-03-20 | 2012-11-08 | The Hong Kong Polytechnic University | Method for diagnosis non-small-cell-lung-carcinoma (nsclc) and classification of its subtypes with different combinations of 6 protein biomarkers |
| US8110675B2 (en) | 2009-06-15 | 2012-02-07 | Chang Gung University | TP expression-inhibiting compound and siRNA sequence thereof |
| US20100317029A1 (en) * | 2009-06-15 | 2010-12-16 | Lih-Chyang Chen | Nasopharyngeal cancer malingancy biomarker and method thereof |
| CN101993919A (zh) * | 2009-08-10 | 2011-03-30 | 芮屈生物技术（上海）有限公司 | 一种pd-ecgf基因的原位杂交检测试剂盒及其检测方法和应用 |
| AU2011223789A1 (en) * | 2010-03-01 | 2012-09-20 | Caris Life Sciences Switzerland Holdings Gmbh | Biomarkers for theranostics |
| JP2014523398A (ja) | 2011-03-23 | 2014-09-11 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗−インテグリンを用いた抗血管新生療法を改良するための方法及び組成物 |
| CA2862835A1 (en) * | 2012-01-13 | 2013-07-18 | Genentech, Inc. | Biological markers for identifying patients for treatment with vegf antagonists |
-
2015
- 2015-03-11 EP EP15382109.5A patent/EP3067698A1/en not_active Withdrawn
-
2016
- 2016-03-10 MX MX2017011467A patent/MX384046B/es unknown
- 2016-03-10 EP EP16709410.1A patent/EP3268744B1/en active Active
- 2016-03-10 WO PCT/EP2016/055143 patent/WO2016142471A1/en not_active Ceased
- 2016-03-10 PL PL16709410T patent/PL3268744T3/pl unknown
- 2016-03-10 AU AU2016231086A patent/AU2016231086B8/en active Active
- 2016-03-10 ES ES16709410T patent/ES2896056T3/es active Active
- 2016-03-10 US US15/556,568 patent/US11802874B2/en active Active
- 2016-03-10 HK HK18109182.9A patent/HK1250582A1/zh unknown
- 2016-03-10 KR KR1020177025613A patent/KR102513020B1/ko active Active
- 2016-03-10 CN CN201680013857.4A patent/CN107667292B/zh active Active
- 2016-03-10 JP JP2017548041A patent/JP2018512585A/ja active Pending
-
2020
- 2020-08-28 JP JP2020144291A patent/JP2020201278A/ja active Pending
-
2022
- 2022-07-15 JP JP2022113650A patent/JP7453284B2/ja active Active
-
2023
- 2023-10-27 US US18/384,508 patent/US12298307B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hoseok et al. | Lung cancer biomarkers | |
| Jiang et al. | Detection and clinical significance of circulating tumor cells in colorectal cancer | |
| e Silva et al. | Assessment of kidney function in patients with cancer | |
| JP2014533960A5 (cg-RX-API-DMAC10.html) | ||
| Gong et al. | Prognostic significance of metadherin overexpression in hepatitis B virus-related hepatocellular carcinoma | |
| JP2013517476A5 (cg-RX-API-DMAC10.html) | ||
| Noguera et al. | Phase II trial of imatinib mesylate in patients with recurrent platinum-and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube | |
| Katono et al. | Clinicopathological significance of S100A10 expression in lung adenocarcinomas | |
| JP2017526916A5 (cg-RX-API-DMAC10.html) | ||
| Ding et al. | Gab2 is a novel prognostic factor for colorectal cancer patients | |
| JP2017529852A5 (cg-RX-API-DMAC10.html) | ||
| Shimura et al. | C-reactive protein is a potential prognostic factor for metastatic gastric cancer | |
| Pan et al. | The Glasgow Prognostic Score is an independent prognostic predictor of hepatocellular carcinoma following radical resection | |
| Kastritis et al. | The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy | |
| Uratani et al. | Preoperative lower body mass index correlates with poorer prognosis in patients undergoing curative laparoscopic surgery for colorectal cancer | |
| Horn et al. | The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer | |
| WO2016161153A3 (en) | Prognostic and diagnostic methods for colorectal cancer | |
| JP2019516104A5 (cg-RX-API-DMAC10.html) | ||
| Asegaonkar et al. | Serum high sensitivity C-reactive protein in breast cancer patients | |
| JP2012515893A5 (cg-RX-API-DMAC10.html) | ||
| JP2016502083A5 (cg-RX-API-DMAC10.html) | ||
| CN104111332A (zh) | 基于蛋白标志物pak4辅助诊断非小细胞肺癌患者的试剂盒 | |
| Laguna | Re: Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904 | |
| Lamarca et al. | Tumoural expression of connective tissue growth factor (CTGF) impacts on survival in patients diagnosed with hepatocellular carcinoma (HCC) | |
| CN103323589A (zh) | 基于血清中il-22表达量预测结直肠癌患者化疗抵抗情况的方法 |